ZNF516 suppresses EGFR by targeting the CtBP/LSD1/CoREST complex to chromatin

EGFR is required for animal development, and dysregulation of EGFR is critically implicated in malignant transformation. However, the molecular mechanism underlying the regulation of EGFR expression remains poorly explored. Here we report that the zinc-finger protein ZNF516 is a transcription repres...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature communications 2017-09, Vol.8 (1), p.691-17, Article 691
Hauptverfasser: Li, Lifang, Liu, Xinhua, He, Lin, Yang, Jianguo, Pei, Fei, Li, Wanjin, Liu, Shumeng, Chen, Zhe, Xie, Guojia, Xu, Bosen, Ting, Xia, Zhang, Zihan, Jin, Tong, Liu, Xujun, Zhang, Wenting, Yuan, Shuai, Yang, Ziran, Wu, Chongyang, Zhang, Yu, Yang, Xiaohan, Yi, Xia, Liang, Jing, Shang, Yongfeng, Sun, Luyang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:EGFR is required for animal development, and dysregulation of EGFR is critically implicated in malignant transformation. However, the molecular mechanism underlying the regulation of EGFR expression remains poorly explored. Here we report that the zinc-finger protein ZNF516 is a transcription repressor. ZNF516 is physically associated with the CtBP/LSD1/CoREST complex and transcriptionally represses a cohort of genes including EGFR that are critically involved in cell proliferation and motility. We demonstrate that the ZNF516–CtBP/LSD1/CoREST complex inhibits the proliferation and invasion of breast cancer cells in vitro and suppresses breast cancer growth and metastasis in vivo. Significantly, low expression of ZNF516 is positively associated with advanced pathological staging and poor survival of breast carcinomas. Our data indicate that ZNF516 is a transcription repressor and a potential suppressor of EGFR, adding to the understanding of EGFR-related breast carcinogenesis and supporting the pursuit of ZNF516 as a potential therapeutic target for breast cancer. EGFR is a well-known oncogene; however, the mechanisms regulating its expression are still unclear. Here, analysing genome-wide chromatin associations, the authors show that in breast cancer cells ZNF516 represses EGFR transcription through the interaction with the CtBP/LSD1/CoREST complex.
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-017-00702-5